Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Diabetic Retinopathy Market

ID: MRFR/MED/48707-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

Japan Diabetic Retinopathy Market Research Report: Size, Share, Trend Analysis By Types (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery), and By End-user (Hospitals & Clinics, Ophthalmology Centers, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Diabetic Retinopathy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Medical Device, BY Type (USD Million)
  49.     4.1.1 Non-Proliferative Diabetic Retinopathy (NPDR)
  50.     4.1.2 Proliferative Diabetic Retinopathy (PDR)
  51.   4.2 Medical Device, BY Treatment (USD Million)
  52.     4.2.1 Pharmacological Therapies
  53.     4.2.2 Laser Treatment
  54.     4.2.3 Surgery
  55.   4.3 Medical Device, BY End User (USD Million)
  56.     4.3.1 Hospitals & Clinics
  57.     4.3.2 Ophthalmology Centers
  58.     4.3.3 Research Institutes
  59. 5 SECTION V: COMPETITIVE ANALYSIS
  60.   5.1 Competitive Landscape
  61.     5.1.1 Overview
  62.     5.1.2 Competitive Analysis
  63.     5.1.3 Market share Analysis
  64.     5.1.4 Major Growth Strategy in the Medical Device
  65.     5.1.5 Competitive Benchmarking
  66.     5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  67.     5.1.7 Key developments and growth strategies
  68.       5.1.7.1 New Product Launch/Service Deployment
  69.       5.1.7.2 Merger & Acquisitions
  70.       5.1.7.3 Joint Ventures
  71.     5.1.8 Major Players Financial Matrix
  72.       5.1.8.1 Sales and Operating Income
  73.       5.1.8.2 Major Players R&D Expenditure. 2023
  74.   5.2 Company Profiles
  75.     5.2.1 Novartis (CH)
  76.       5.2.1.1 Financial Overview
  77.       5.2.1.2 Products Offered
  78.       5.2.1.3 Key Developments
  79.       5.2.1.4 SWOT Analysis
  80.       5.2.1.5 Key Strategies
  81.     5.2.2 Regeneron Pharmaceuticals (US)
  82.       5.2.2.1 Financial Overview
  83.       5.2.2.2 Products Offered
  84.       5.2.2.3 Key Developments
  85.       5.2.2.4 SWOT Analysis
  86.       5.2.2.5 Key Strategies
  87.     5.2.3 Roche (CH)
  88.       5.2.3.1 Financial Overview
  89.       5.2.3.2 Products Offered
  90.       5.2.3.3 Key Developments
  91.       5.2.3.4 SWOT Analysis
  92.       5.2.3.5 Key Strategies
  93.     5.2.4 Bayer (DE)
  94.       5.2.4.1 Financial Overview
  95.       5.2.4.2 Products Offered
  96.       5.2.4.3 Key Developments
  97.       5.2.4.4 SWOT Analysis
  98.       5.2.4.5 Key Strategies
  99.     5.2.5 Alcon (CH)
  100.       5.2.5.1 Financial Overview
  101.       5.2.5.2 Products Offered
  102.       5.2.5.3 Key Developments
  103.       5.2.5.4 SWOT Analysis
  104.       5.2.5.5 Key Strategies
  105.     5.2.6 Pfizer (US)
  106.       5.2.6.1 Financial Overview
  107.       5.2.6.2 Products Offered
  108.       5.2.6.3 Key Developments
  109.       5.2.6.4 SWOT Analysis
  110.       5.2.6.5 Key Strategies
  111.     5.2.7 Santen Pharmaceutical (JP)
  112.       5.2.7.1 Financial Overview
  113.       5.2.7.2 Products Offered
  114.       5.2.7.3 Key Developments
  115.       5.2.7.4 SWOT Analysis
  116.       5.2.7.5 Key Strategies
  117.     5.2.8 Horizon Therapeutics (IE)
  118.       5.2.8.1 Financial Overview
  119.       5.2.8.2 Products Offered
  120.       5.2.8.3 Key Developments
  121.       5.2.8.4 SWOT Analysis
  122.       5.2.8.5 Key Strategies
  123.     5.2.9 Eyenovia (US)
  124.       5.2.9.1 Financial Overview
  125.       5.2.9.2 Products Offered
  126.       5.2.9.3 Key Developments
  127.       5.2.9.4 SWOT Analysis
  128.       5.2.9.5 Key Strategies
  129.   5.3 Appendix
  130.     5.3.1 References
  131.     5.3.2 Related Reports
  132. 6 LIST OF FIGURES
  133.   6.1 MARKET SYNOPSIS
  134.   6.2 JAPAN MARKET ANALYSIS BY TYPE
  135.   6.3 JAPAN MARKET ANALYSIS BY TREATMENT
  136.   6.4 JAPAN MARKET ANALYSIS BY END USER
  137.   6.5 KEY BUYING CRITERIA OF MEDICAL DEVICE
  138.   6.6 RESEARCH PROCESS OF MRFR
  139.   6.7 DRO ANALYSIS OF MEDICAL DEVICE
  140.   6.8 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
  141.   6.9 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
  142.   6.10 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
  143.   6.11 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
  144.   6.12 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
  145.   6.13 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
  146.   6.14 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
  147.   6.15 MEDICAL DEVICE, BY END USER, 2024 (% SHARE)
  148.   6.16 MEDICAL DEVICE, BY END USER, 2024 TO 2035 (USD Million)
  149.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  150. 7 LIST OF TABLES
  151.   7.1 LIST OF ASSUMPTIONS
  152.     7.1.1
  153.   7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  154.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  155.     7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  156.     7.2.3 BY END USER, 2025-2035 (USD Million)
  157.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  158.     7.3.1
  159.   7.4 ACQUISITION/PARTNERSHIP
  160.     7.4.1

Japan Medical Device Market Segmentation

Medical Device By Type (USD Million, 2025-2035)

  • Non-Proliferative Diabetic Retinopathy (NPDR)
  • Proliferative Diabetic Retinopathy (PDR)

Medical Device By Treatment (USD Million, 2025-2035)

  • Pharmacological Therapies
  • Laser Treatment
  • Surgery

Medical Device By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Ophthalmology Centers
  • Research Institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓